Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 07:45 ET | Source: Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase...
October 28, 2025 16:05 ET | Source: Vivani Medical, Inc.

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
October 26, 2025 19:15 ET | Source: Vivani Medical, Inc.

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
October 22, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025

ALAMEDA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
October 03, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off

ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
September 24, 2025 09:15 ET | Source: Vivani Medical, Inc.

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra...
September 17, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision...
September 04, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory...
August 20, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
August 13, 2025 16:20 ET | Source: Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1...